Release Date: December 23, 2025
Expiration Date: December 23, 2026
Activity Overview
This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of platinum-resistant ovarian cancer, with a forward-looking perspective on how new and novel agents might impact clinical practice. Mechanisms of action and clinical trial data for novel antibody-drug conjugates, glucocorticoid receptor inhibitors, and oncolytic viruses will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.
Target Audience
This educational activity is directed toward community and academic-based medical oncologists, gynecologic oncologists, NPs/PAs, nurses, pharmacists, and other health care providers interested in the treatment of ovarian cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Incorporate the latest evidence and guideline recommendations on currently available agents into personalized treatment strategies for patients with platinum-resistant ovarian cancer (PROC)
- Describe key features and novel mechanisms of emerging therapies under investigation for the treatment of PROC
- Evaluate the efficacy and safety of emerging therapies for PROC, including antibody-drug conjugates, glucocorticoid receptor modulators, and novel immunotherapies
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here